NIAID announces funding opportunity for MCM research and development

The National Institute of Allergy and Infectious Diseases recently announced a funding opportunity focused on the generation, validation and advancement of medical countermeasures to emerging and re-emerging infectious diseases.

The NIAID's Centers for Excellence in Translational Research program is meant to support multidisciplinary translational research for the development of MCMs. Each of the NIAID's 11 centers will be organized around a single theme addressing a targeted countermeasure or technology. The themes can range from development of a single countermeasure to the development of new technologies meant to target a wide array of pathogens.

Some examples of research themes the funding opportunity announcement cites include new or improved therapeutics against antibiotic-resistant pathogens, the development of a broad-spectrum technology or countermeasure, countermeasures targeting intracellular pathogens, the development of a multivalent vaccine, host-targeted therapeutics or interventions as therapeutics, and improved vaccine technologies or production platforms.

Each application must define the proposed center theme, the range of activities being pursued and the significance of the center theme. The NIAID encourages centers focused on the development of countermeasures that are effective against a variety of toxins and pathogens, platforms that reduce the time and cost of new products, and technologies that can be widely applied to improve product classes.

Letters of intent for the funding opportunity are due February 26. Applications are due on March 26.